Search Results - Lucy, Lela

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts by Dombret, Hervé, Seymour, John F., Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Noppeney, Richard, Stone, Richard M., Minden, Mark D., McIntyre, Heidi, Songer, Steve, Lucy, Lela M., Beach, C.L., Döhner, Hartmut

    Published in Blood
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

    Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial by KROPFF, Martin, GIONGCO BAYLON, Honorata, AVET-LOISEAU, Herve, MOEHLER, Thomas M, PATTOU, Claire, LUCY, Lela, KUEENBURG, Elisabeth, GLASMACHER, Axel, ZERBIB, Robert, FACON, Thierry, HILLENGASS, Jens, ROBAK, Tadeusz, HAJEK, Roman, LIEBISCH, Peter, GORANOV, Stefan, HULIN, Cyrille, BLADE, Joan, CARAVITA, Tommaso

    Published in Haematologica (Roma)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

    The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS) by Seymour, John F., Silverman, Lewis R., Döhner, Hartmut, Fenaux, Pierre, Mufti, Ghulam J., Santini, Valeria, Minden, Mark D., Stone, Richard M., Lucy, Lela M., Songer, Stephen, Dougherty, Donna, Hinkle, Randy, Gambini, Dominique, Beach, C.L., Dombret, Hervé

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

    Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of th... by Döhner, Hartmut, Seymour, John F, Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Cavenagh, James D, Kumar, Rajat, Schuh, Andre C, Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Stone, Richard M., Minden, Mark D., McIntyre, Heidi, Songer, Stephen, Lucy, Lela M., Beach, CL, Dombret, Hervé

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

    Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Change... by Seymour, John F, Döhner, Hartmut, Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Cavenagh, James D, Kumar, Rajat, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Stone, Richard M, Minden, Mark D., McIntyre, Heidi, Songer, Stephen, Lucy, Lela M., Beach, CL, Dombret, Hervé

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine

    Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine by Shi, Tao, Danilova, Ludmila, Luo, Xiaolong, Lucy, Lela M., Beach, CL, Cope, Leslie, Herman, James G., MacBeth, Kyle J.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

    Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline T... by Seymour, John F, Santini, Valeria, Fenaux, Pierre, Giagounidis, Aristoteles A.N., Sanz, Guillermo F., Finelli, Carlo, Lucy, Lela M., Backstrom, Jay, Beach, CL

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk

    Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk by Gattermann, Norbert, Sanz, Guillermo F., Giagounidis, Aristoteles, Seymour, John F, Fenaux, Pierre, Santini, Valeria, Mufti, Ghulam J., Muus, Petra, Ramos, Fernando, Lucy, Lela M., Beach, CL, Silverman, Lewis R.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma

    OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma by Kropff, Martin, Baylon, Honorata Giongco, Hillengass, Jens, Robak, Tadeusz, Hajek, Roman, Liebisch, Peter, Goranov, Stefan, Hulin, Cyrille, Blade, Joan, Caravita, Tomaso, Avet-Loiseau, Herve, Moehler, Thomas M., Pattou, Claire, Lucy, Lela, Kueenburg, Elisabeth, Glasmacher, Axel, Zerbib, Robert, Facon, Thierry

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: